Skip to main content

CSU Critiques Of Traffic Coalition Plan To Legalize Cannabis Meets Wide Mockery

CSU leader Markus Söder and Federal Health Minister Karl Lauterbach trade barbs over current government drug policy – which goes viral on German Twitter

It all began so innocently. Markus Söder, the leader of the “opposition” to the current parties comprising the Traffic Light Coalition, threw a weighted barb at the government’s drug policy during the CDU party congress in Hanover last weekend. Söder claimed that the legalization of cannabis would automatically lead to the legalization of drugs such as crystal methamphetamine (a highly addictive and dangerous street drug).

There were two problems with the approach. The first is that one of the parties now making up the coalition government, the Greens, did call for the legalization of “party drugs,” specifically cocaine, ecstasy, and amphetamines – but not crystal meth – in August. This is, however, not in the platform of the Traffic Light Coalition – which is only planning to legalize cannabis. A draft bill is expected to be made public either at the end of this year or early in 2023.

The second however, no doubt prompted by the above inaccuracies, was that Söder mispronounced the name of the drug – and instead, referred to the drug as “crystal mett.”

And this set off a rapid fire, and often humorous response.

Social Media Mockery

It was not only Lauterbach who mocked the mispronouncement on Twitter. His response? “Despite the scathing criticism from Markus Söder that the legalization of cannabis promotes the use of Crystal-Mett, we will not slow down on the same. At least vegetarians will remain safe.” Lauterbach was making a pun connecting the mispronunciation of the name of the drug to the German word for a chopped raw meat spread, frequently served with onions on bread.

This in turn set off an imaginative interchange where German Twitter users posted multiple pictures of what a “meat drug” might look like – or how it might be consumed.

This particularly imaginative response showing an addict applying heat to a spoonful of the referenced meat spread and then injecting it directly into his veins is entitled “The really hard stuff.”

The responses – both from the Health Minister and the Twitterverse seem to reflect the fact that Germans are rapidly warming to the idea of recreational cannabis reform – especially as the majority of the country is behind medical use.

This is a very good sign for the passage of full cannabis legalization sometime in the next 18-24 months aus Deutschland.

Canadian Case Study Finds Favorable Results For CBD Oil And Autism

It is estimated that over 75 million people worldwide have been diagnosed with autism, with countless other people going undiagnosed for one reason or another. The first diagnosis of autism occurred roughly 75 years ago, and the definition of what constitutes autism has evolved since that time.

Currently, autism is defined by Autism Speaks as, “a broad range of conditions characterized by challenges with social skills, repetitive behaviors, speech and nonverbal communication.”

The most common types of developmental therapy for people with autism include speech and language therapy, which has been found to improve the person’s understanding and use of speech and language, particularly in social interactions.

A recent study in Canada found that CBD oil may be an effective treatment for those diagnosed with autism. Below is more information about it via a news release from NORML:

Toronto, Canada: The administration of plant-derived CBD oil is safe and effective in the treatment of autism-related symptoms and it ought to be considered as a viable treatment option for patients with the disorder, according to the findings of a case study published in the journal Cureus.

A team of Canadian investigators assessed the long-term use of CBD oil containing 20 mg of CBD and less than one mg of THC in a non-verbal pediatric patient with autism spectrum disorder. Prior to initiating CBD treatment, the patient exhibited behavioral symptoms with outbursts of anger and physical aggression (e.g., punching, kicking, biting, head-butting, and scratching).

Following twice-daily CBD treatment, the patient “experienced a reduction in negative behaviors, including violent outbursts, self-injurious behaviors, and sleep disruptions. There was an improvement in social interactions, concentration, and emotional stability.”

Investigators concluded: “In the case study presented, the child patient has shown behavioral and cognitive improvements with no side effects reported. … With the increasing clinical studies on the use of cannabidiol in treating patients with mood disorders, anxiety, chronic pain conditions, and other behavioral problems, it should be considered as a treatment option in managing symptoms related to autism.”

The findings are consistent with numerous other studies demonstrating that the use of either CBD-dominant cannabis or oral extracts is associated with symptom mitigation in children with ASD.

Full text of the study, “Cannabidiol in treatment of autism spectrum disorder: A case study,” appears in Cureus. Additional information on cannabis and ASD is available from NORML.

People In London Support Cannabis Decriminalization By Wide Margin

Back in May we reported that London Mayor Sadiq Khan announced that a commission would be launched to explore, among other things, cannabis policy reform. Cannabis reform is spreading across the European continent at an ever-increasing rate in most countries, however, the United Kingdom is not one of them.

When cannabis reform cannot be achieved at a national level, it’s wise for cannabis activists to focus their efforts locally. If enough local victories are won it builds momentum for larger reform efforts at a higher level.

With that in mind, any changes in cannabis policy and/or enforcement in London would be a great thing, and that appears to be something that many Londoners support according to the results of a new poll. Per excerpts from YouGov:

New YouGov data finds that Londoners support decriminalising cannabis within the boundaries of the capital by 50% to 33%. However opinion is divided across party lines, with 64% of the capital’s Labour voters supporting such a move compared to only 34% of Conservative voters.

Younger Londoners are also notably more likely to support a change in the law, with 52% of 18-24s and 56% of 25-49-year-olds supporting decriminalisation, versus 45% of 50-64 year olds and 34% of those aged 65 and over.

Of course, 17% of poll participants indicated that they ‘didn’t know’ whether they support cannabis decriminalization or not. However, it’s a safe bet that many of them, if properly educated on the subject, would move from the ‘don’t know’ category to ‘support.’

It’s also likely a safe bet that many people that do support cannabis reform refrained from indicating so when asked for fear of being subjected to persecution and/or stigma. It’s a phenomenon that is regularly found in cannabis polling.

Polls consistently demonstrate a lower level of support than there actually is, as proven by comparing polling results and election results in places that vote on cannabis.

THC Provides Symptomatic Relief To Patients With Tourette Syndrome

As many as one percent of people worldwide suffer from Tourette Syndrome to some degree, although many cases go undiagnosed. Tourette Syndrome is a nervous system disorder that involves the patient making repetitive movements and/or unwanted sounds.

Most cases of Tourette’s Syndrome start when the sufferer is a child, with some cases getting worse as the patient gets older. Typical treatments for Tourette Syndrome includes pharmaceutical medications and/or psychological therapies.

Cannabis is another form of treatment for Tourette Syndrome, albeit an emerging form of treatment that is not as common. A recent study in Canada found cannabis to be effective in some cases. Below is more information about it via a news release from NORML:

Toronto, Canada: Vaporized cannabis containing ten percent THC provides symptomatic relief to patients with Tourette Syndrome (TS), according to placebo-controlled data published in the journal Cannabis and Cannabinoid Research.

Canadian researchers assessed the short-term effects of vaporized cannabis of varying potencies versus placebo in nine patients with TS.

They reported that subjects exhibited and perceived modest improvements following the administration of THC-dominant cannabis, but that they failed to demonstrate similar improvements following the use of either lower THC cannabis and/or high-CBD cannabis. Researchers acknowledged, “[G]iven the small sample size, … it is difficult to draw definitive conclusions about the benefits of THC.”

Prior studies assessing the long-term use of oral THC have documented a reduction in tics in TS patients. The findings of a 2019 study concluded, “Medical cannabis seems to hold promise in the treatment of GTS [Gilles de la Tourette syndrome] as it demonstrated high subjective satisfaction by most patients however not without side effects and should be further investigated as a treatment option for this syndrome.”

Full text of the study, “A double-blind, randomized, controlled crossover trial of cannabis in adults with Tourette Syndrome,” appears in Cannabis and Cannabinoid Research. Additional information on cannabis and TS is available from NORML.

UK Study Finds Cannabis Consumption Is Not Linked To Changes In Motivation

Historically, cannabis consumers have been portrayed by cannabis opponents as lazy ‘do nothings’ that sit on couches all day eating potato chips. Those stereotypes have also been perpetuated in mainstream media.

Unfortunately for cannabis opponents, there are numerous examples of people in peak physical condition that consume cannabis every single day, as demonstrated by the growing number of professional athletes that are coming out of the cannabis closet.

To be fair, there are certainly cannabis consumers that lack motivation, however, it’s not because of the cannabis. Some people are just lazy. That is reflected in the results of a recent study out of the United Kingdom. Below is more information about it via a news release from NORML:

London, United Kingdom: Neither adults nor young people who consume cannabis exhibit symptoms of so-called ‘a-motivational syndrome,’ according to case control data published in The International Journal of Neuropsychopharmacology.

British researchers assessed apathy, anhedonia (an inability to feel pleasure), and effort-based decision making in a cohort of late-adolescent and young adult cannabis consumers. Their performance was compared to that of age-matched controls (non-cannabis consumers).

Researchers identified no significant differences between the two groups.

“Cannabis use has historically been linked with a-motivation, which is reflected in prevalent, pejorative ‘lazy stoner’ stereotypes. In this study, we counter this cliché by showing that a relatively large group of adult and adolescent cannabis users and controls did not differ on several measures of reward and motivation,” they concluded. “Specifically, people who used cannabis on average four days per week did not report greater apathy or anhedonia, reduced willingness to expend effort for reward, or reduced reward wanting or liking compared to people who did not use cannabis. … Our results add to the growing body of evidence suggesting that non-acute cannabis use is not linked with amotivation, which may help to reduce stigma experienced by people who use cannabis.”

The investigators’ findings are consistent with those of other recent studies refuting long standing claims that those with a history of marijuana use typically lack motivation.

Full text of the study, “Anhedonia, apathy, pleasure, and effort-based decision-making in adult and adolescent cannabis users and controls,” appears in The International Journal of Neuropsychopharmacology.

German Poll: More Than 60 Percent Support Cannabis Legalization

Germany is in the midst of a cannabis legalization effort that is more complicated and robust than anything that has ever occurred since the dawn of cannabis prohibition so many decades ago. After the dust settled on Germany’s last federal election in 2021, the incoming coalition government announced plans to move Germany toward launching a regulated adult-use cannabis industry. The current governing German coalition, commonly referred to as the ‘Traffic Light Coalition,’ has worked since late 2021 to explore various public policy components of legalization. According to the results of a new poll from Ipsos, a strong majority of Germans support the effort.

Per Ipsos‘ news release announcing the results of the poll, “61 percent of those surveyed say they would support the controlled sale of cannabis in licensed stores. Only 39 percent consider the plans to legalize cannabis to be irresponsible and fundamentally reject legal sale and consumption.” The survey was conducted online between September 2 and 4, 2022, and involved 1,000 eligible voters between the ages of 18 and 75 in Germany.

Diving Into The Results

Fortunately, there’s majority support for legalization among all age categories (18-75), however, there are statistical differences between age groups. While 61% of the poll’s participants support adult-use cannabis legalization, roughly 55% of people aged 60-75 were supportive. That is quite a bit less than the level of support among poll participants that were aged 18-39 (65%). Sixty two percent of poll participants aged 40-59 years old expressed support for legalization.

The level of support for cannabis legalization does not extend to the legalization of other banned substances in Germany. When poll participants were asked if other substances should be legalized in addition to cannabis, 95% of people expressed opposition to such a public policy change. The overwhelming level of opposition was found across age groups, although younger poll participants were more likely to express support for further legalization compared to older poll participants.

Not An Easy Lift

The current general consensus for when regulated adult-use products will actually be available for legal purchase in Germany seems to be by the year 2025. After the results of the 2021 federal election in Germany became final there was hope for legalization to become a reality in 2022. However, time has proven that hope to be a bit too ambitious.

The fact of the matter is that what German lawmakers and regulators are trying to do is something that has never been done before, at least not at the same scale. Sure, Canada and Uruguay have implemented legal adult-use sales, yet those markets pale in comparison to the size and complexity of Germany’s market. Germany has a much larger population compared to Canada and Uruguay combined, and Germany’s geographical location makes things that much more complex to navigate.

I am personally hopeful that there will be multiple steps to implementing legalization in Germany. After all, there is no need to wait for sales regulations to be formulated before implementing personal possession, consumption, and cultivation provisions. Clearly, cannabis prohibition is a failed public policy in Germany and it would be wise for lawmakers to implement as many legalization provisions as possible that pertain to individual consumers prior to finalizing provisions geared towards regulated sales.

Attend CanEx Jamaica Business Conference And Expo September 15-17th, 2022

The fifth installment of CanEx Business Conference and Expo is taking place in Montego Bay, Jamaica from September 15-17, 2022. The CanEx Jamaica Business Conference and Expo is an annual business-to-business (B2B) event that brings together global cannabis industry experts.

The conference will provide insight into the global direction of the industry and will feature a mix of high-level discourse and practical opportunities led by global experts with real-life applications in the cannabis industry. Presenters will discuss opportunities for investment, medical advances and uses, and the current legal landscape of the emerging global cannabis industry.

Event attendees can look forward to numerous networking events that will host robust panel discussions on such topics as:

  • Cannabis for All: Ensuring Equitable Cannabis Regulation
  • Psychedelics: Transforming Mental Health Options
  • Developing A Dynamic Cannabis Industry in Jamaica
  • Understanding Today’s Cannabis Investment Climate
  • Reggae Music, Cannabis Culture, and Embracing the NFT Opportunity

Leading up to the event, organizers interviewed the conference’s four keynote speakers – Founder and CEO of Simply Pure Wanda James, President and CEO of the Marijuana Policy Project Toi Hutchinson, renowned cell biologist Dr. Annabelle Manalo-Morgan, and President and CEO of Bhang Inc. Jamie L Pearson. Below is what the speakers had to say about CanEx Jamaica:

“I’ve always wanted to contribute to cannabis research in the Caribbean. My husband Gramps Morgan and the Morgan Heritage family are from the beautiful hills of St. Thomas Jamaica which has the ability to grow incredible organic cannabis, so Jamaica is very dear to me. I have always heard about Canex bringing experts in from all over the world to share their knowledge. That collaborative effort that Canex works hard to portray is what helps drive this industry forward. Cannabis is global and we need to come together and talk. Canex provides us with that platform!” stated Dr. Annabelle Manalo-Morgan.

“CanEx offers an unparalleled opportunity for aspiring entrepreneurs, investors, policymakers, and advocates to shape the future of cannabis legalization in the Caribbean and beyond. Anyone looking to advance the growing cannabis movement in the region and worldwide should attend to learn, connect, and grow.” stated President and CEO of the Marijuana Policy Project Toi Hutchinson.

“The incredible quality of both education and experience. You’ll have outstanding content, fun downtime events where the networking magic happens, The Who’s Who of the industry to network with, and all set in a beautiful location that has a burgeoning cannabis market which makes the intensive work of participating wholeheartedly in a conference both more enjoyable and also incredibly productive. When you invest precious resources (ie time and money) to attend an event like CanEx, getting so much out of these four days is awesome!” stated President and CEO of Bhang Inc. Jamie L Pearson.

“It gives me great pleasure to bring the world to Jamaica to hear about the cannabis industry, the potential for wealth, and the potential Job creation. It gives me great pleasure to invite the mostly white legal industry to a Black country. I believe Canex Jamaica is an amazing intersection of how large the industry can become, and the exploration and education of the
culture of ganja.” stated Founder and CEO of Simply Pure Wanda James.

A limited number of tickets to CanEx Jamaica are still available. Find out more at: canexjamaica.com

Liz Truss Makes It Clear Where She Stands On Cannabis Policy

Cannabis reform is one of the most popular political issues on earth right now, particularly in North America and Europe. At a time when it seems like people rarely agree on anything, cannabis is one area of public policy where support is strong and cuts across party lines. Unfortunately, that support does not appear to extend to the office of the United Kingdom’s Prime Minister, with the UK announcing this week that it is officially blocking a cannabis reform measure that was previously passed by lawmakers in Bermuda earlier this year.

Liz Truss took over as Prime Minister in the United Kingdom this week, and shortly after taking office her government announced the official blockage of the cannabis reform measure in Bermuda. Cannabis policy observers around the globe were hopeful that upon taking office that Truss would pursue a new era for cannabis policy in the UK, however, being that she is blocking cannabis reform elsewhere it’s very clear where she stands when it comes to cannabis policy.

Actions Speak Louder Than Words

Truss, like many politicians, has a checkered past when it comes to cannabis policy. Leading up to the Prime Minister transition in the UK, Truss was criticized by opponents for her previously expressed support for cannabis reform. Apparently, a leaflet edited by Liz Truss when she was a leading Lib Dem at Oxford University surfaced in which it was asked if cannabis should be legalized, a position that Truss reportedly supported back then.

The newly installed Prime Minister has been criticized by both cannabis supporters and opponents for ‘flip flopping’ on the issue, with many asking the logical question, ‘where does Liz Truss really stand when it comes to cannabis reform?’ Unfortunately, we found out the answer to that question this week, and it wasn’t a favorable answer.

Politicians of all backgrounds and at all levels will often tell voters what they think they want to hear. It is no secret that many people who seek public office will say whatever it takes to get elected, even if what they are saying to one audience completely contradicts what they are telling a different audience. That is politics as usual, and the real measure of a politician on any given issue is what actions they take (or do not take) once they get into a position to actually do something regarding the particular issue.

Colonization on Full Display

In order for cannabis reform to move forward in Bermuda, the measure has to receive blessing from the United Kingdom in the form of ‘royal assent.’ It’s a concept that is born out of the United Kingdom’s (Britain) colonization of Bermuda centuries ago. Bermuda remains the oldest British colony in existence, which in itself needs to be addressed.

Lawmakers in Bermuda deserve to set their own laws. No one in the United Kingdom should be able to prevent a law from taking effect in Bermuda, whether it’s related to cannabis or anything else. Citizens in Bermuda elect their own representatives, and those representatives should be able to carry out ‘the people’s work’ without interference from countries across the Atlantic Ocean.

Fortunately, it sounds like lawmakers in Bermuda are going to proceed forward with their plans despite the opposition by Liz Truss’ government. It sets up a constitutional showdown between the UK and Bermuda, and in the first week of Truss’ tenure as Prime Minister no less. With all of the problems out there in the world, it’s a shame that any time and effort is being spent on preventing the will of Bermuda’s citizens. The only ‘benefit’ to the saga is that it makes clear where Liz Truss stands on cannabis policy, for better or worse.

Study Associates Cannabis Use With Lower BMI Among Those With HIV/HCV

As of 2020, it was estimated that roughly 38.4 million people around the world have HIV. HIV is a very serious health condition that causes AIDS and interferes with the body’s ability to fight against infections.

It is estimated that roughly 58 million people around the globe have hepatitis C. Hepatitis C is a viral infection that can cause the liver to become inflamed, and if not properly treated, hepatitis C can lead to serious liver damage in suffering patients.

Many people that are diagnosed with either HIV or HCV also suffer from the other condition as well. As with virtually every health condition, having a healthy body mass index (BMI) is important. A recent study in France found that medical cannabis use was associated with a lower BMI in patients diagnosed with HIV and HCV. Below is more information about it via a news release from NORML:

Marseille, France: People co-infected with HIV and hepatitis C who consume cannabis are at a lower risk of being overweight, according to data published in the journal AIDS Education and Prevention.

French investigators assessed the relationship between cannabis use and body mass index (BMI) in a cohort of 992 HIV/HCV patients. Consistent with prior research, they reported that a history of marijuana use was “inversely associated with BMI.”

Prior studies involving HIV/HCV subjects have also identified a link between cannabis use and a lower risk of diabetesfatty liver disease, and early mortality.

Other case control studies have consistently reported that those with a history of marijuana use are less likely than abstainers to be obese or to suffer from type 2 diabetes.

Full text of the study, “Cannabis use as a protective factor against overweight in HIV-hepatitis C virus co-infected people,” appears in AIDS Education and Prevention. Additional information on cannabis and HIV/AIDS is available from NORML.